A Phase I/Ib Open-label, Multi-center, Dose Escalation Study of GWN323 (Anti-GITR) as a Single Agent and in Combination With PDR001 (Anti-PD-1) in Patients With Advanced Solid Tumors and Lymphomas
The Phase I/Ib study of GWN323 (anti-GITR) in combination with PDR001 (anti-PD-1) represents a strategic initiative by Novartis Pharmaceuticals to enhance the therapeutic landscape for patients with advanced solid tumors and lymphomas. Given the increasing interest in immuno-oncology therapies, this dual-target approach may provide a competitive edge in a crowded market. The trial's completion and subsequent data analysis will be critical in determining the viability of GWN323 as a standalone treatment and in combination therapy, potentially positioning Novartis favorably against competitors in the immunotherapy space. The enrollment of approximately 264 patients indicates a significant investment in understanding the safety and efficacy of these agents, which could lead to future regulatory submissions and market entry.
Indication: Solid Tumors
Modality: small molecule
Target: GITR (Glucocorticoid-Induced TNFR-Related Protein) and PD-1 (Programmed Cell Death Protein 1)
Sponsor: Novartis Pharmaceuticals
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 02, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: GITR (Glucocorticoid-Induced TNFR-Related Protein) and PD-1 (Programmed Cell Death Protein 1)
View original source fields
Condition raw: Solid Tumors, Lymphomas
Condition normalized: Solid Tumors, Lymphomas
Modality raw: small molecule
Modality normalized: small molecule
Target raw: GITR (Glucocorticoid-Induced TNFR-Related Protein) and PD-1 (Programmed Cell Death Protein 1)
Target normalized: GITR (Glucocorticoid-Induced TNFR-Related Protein) and PD-1 (Programmed Cell Death Protein 1)